Quality Of Life in Prostate Cancer Patients Initiating Triptorelin (QOCPIT)
QOCPIT (Quality Of Life in Prostate Cancer Patients Initiating Triptorelin): A Prospective Observational Study to Evaluate Baseline Factors That Stabilize or Improve Health-related Quality of Life.
Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.
The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.
Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.
This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.
Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.
Przegląd badań
Status
Status
Warunki
Warunki
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Ipsen Clinical Study Enquiries
- Numer telefonu: See email
- E-mail: clinical.trials@ipsen.com
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.
Opis
Inclusion Criteria:
Patients are eligible to be included in the study only if all the following criteria apply:
- Males ≥18 years old.
- Patient with histologically confirmed PCa.
- Patient eligible to start triptorelin in its labelled indication for at least 6 months and for whom the decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study.
- Patient able to understand and complete study-related questionnaires.
- Patient having been informed and not opposed to participating in the study.
- Patient covered by healthcare insurance.
Exclusion Criteria
Patients will not be included in the study if they meet any of the following criteria:
- Patient currently participating in any interventional clinical trial.
- Patient who received a hormonal treatment during the last 6 months before inclusion (or hormonal treatment whose duration of action may impact the 6 months before inclusion).
- Patient under tutorship or curatorship; patients under safeguard of justice or deprived of his liberty by an administrative or court decision.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score
Ramy czasowe: At 6 months
|
At 6 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Participants' baseline demographic characteristics
Ramy czasowe: At baseline
|
Including:
|
At baseline
|
|
Participants' clinical characteristics at baseline
Ramy czasowe: At baseline
|
Including:
|
At baseline
|
|
Prostate cancer characteristics at diagnosis and baseline
Ramy czasowe: At baseline
|
Including:
|
At baseline
|
|
Participants symptoms at baseline
Ramy czasowe: At baseline
|
At baseline
|
|
|
Participants' PCa treatment patterns at baseline
Ramy czasowe: At baseline
|
|
At baseline
|
|
Participants' healthcare pathway/supportive care done or planned
Ramy czasowe: At baseline
|
Including:
|
At baseline
|
|
Evolution of PCa at 6-month follow-up according to investigator's opinion
Ramy czasowe: At 6 months
|
Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression. |
At 6 months
|
|
Symptoms and biological characteristics at 6 months
Ramy czasowe: At 6 months
|
At 6 months
|
|
|
Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire
Ramy czasowe: At 6 months
|
The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity. |
At 6 months
|
|
Participants' Quality Of life (QoL)
Ramy czasowe: At baseline and at 6 months
|
|
At baseline and at 6 months
|
|
Participants' PCa treatment patterns at 6 months
Ramy czasowe: At baseline and at 6 months
|
|
At baseline and at 6 months
|
|
Participants' healthcare pathway/supportive care at 6 months
Ramy czasowe: At 6 months
|
• Participant's healthcare pathway/type of supportive care in case of changes. |
At 6 months
|
|
Identification of factors associated with participant's quality of life
Ramy czasowe: At 6 months
|
• Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: ]-3;3[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model. |
At 6 months
|
|
Percentage of participants with adverse events
Ramy czasowe: From enrollment to Month 6
|
An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up. |
From enrollment to Month 6
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: Ipsen Medical Director, Ipsen
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- CLIN-52014-030
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Ramy czasowe udostępniania IPD
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Kryteria dostępu do udostępniania IPD
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .